ERBB2 and cancer: Interestingly, the inhibition of the PI3K-Akt-mTOR signaling pathway with a PI3K and mTOR dual inhibitor (NVP-BEZ235) was shown to be effective in reducing viable HER2-driven cancer cells [27].